MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Transcranial Direct Current Stimulation (tDCS) to Enhance Cognitive Function in Parkinson’s Disease: A Systematic Review and Meta-analysis with Implications for African Healthcare

    O. Uwishema (Kigali, Rwanda)

    Objective: This study assesses the efficacy of transcranial direct current stimulation (tDCS) in improving cognitive function in Parkinson’s disease (PD) patients and explores its relevance…
  • 2025 International Congress

    Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.

    P. Alladi, S. Choudhury, H. Jyothi, R. Bhavani, V. Holla, A. Mahadevan, N. Kamble, P. Pal, R. YADAV. (Bengaluru, India)

    Objective: To estimate levels of complement factor H (CFAH), phosphorylated alpha-syn (p- a-syn), gelsolin, carnosine dipeptidase-1 (CNDP1) and DKK3 in serum of Parkinson’s disease (PD) patients…
  • 2025 International Congress

    Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program

    N. Yousefzadeh, L. Hom, A. Defrank, M. Mccrossin, L. Rubin (Glen Cove, USA)

    Objective: To evaluate medication safety strategies implemented to reduce medication errors in an i-MINC Program Background: Medication mismanagement may lead to critical patient harm in…
  • 2025 International Congress

    Anti-Parkinsonian effects of Globimetula cupulata leaf extract and its underlying mechanisms in 6-hydroxydopamine-lesioned rat model

    A. Hamadjida, R. Ayissi Mbomo, S. Minko, F. Ntchapda, J. Mingoas Kilekoung (BERTOUA, Cameroon)

    Objective: To evaluate the neuroprotective effects of Globimetula cupulata in a rat model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum,…
  • 2025 International Congress

    Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease

    A. López Lobato, D. Náfate Wences, A. Hernández Medrano, A. Cervantes Arriaga, M. Rodriguez Violante (Mexico, Mexico)

    Objective: To evaluate the association between Cannabidiol (CBD) usage and cognitive performance, measured by The Montreal Cognitive Assessment (MoCA) in people living with Parkinson's Disease…
  • 2025 International Congress

    Therapeutic Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Badran, M. Gbreel (Cairo, Egypt)

    Objective: To assess the safety and effectiveness of GLP-1 RAs in patients with PD. Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by…
  • 2025 International Congress

    Effects of Exogenous Melatonin on Sleep and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    M. Alghaniem, A. Abunamoos, F. Qtaishat, A. Rababah, M. Abu Hasna, Y. Aljazi, M. Mustafa, F. Alnajjar, T. Patel, N. Hamam (Amman, 11942, Jordan)

    Objective: To evaluate melatonin's efficacy in enhancing sleep and motor symptoms in Parkinson’s disease (PD) through an updated systematic review and meta-analysis. Background: Sleep disturbances…
  • 2025 International Congress

    Barriers to Healthcare Utilization and Adherence to Medications among People Living with Parkinson’s Disease in Senegal

    M. Njohjam, M. Fall, F. Niakam, J. Kahwagi, A. Diop, M. N, A. Diop (Dakar, Senegal)

    Objective: To explore the barriers to healthcare utilization and adherence to medications among people living with Parkinson’s disease in Senegal, and propose context-informed strategies to…
  • 2025 International Congress

    Predicting Parkinson’s disease severity and cognitive decline using blood-based ferroptotic biomarkers

    V. Huin, E. Cailliau, G. Garçon, M. Dutheil, O. Simonin, N. Beauval, J. Labreuche, D. Blum, C. Moreau, E. Hainque, A. Marques, A. Eusebio, I. Benatru, C. Brefel-Courbon, D. Maltete, C. Giordana, M. Tir, S. Thobois, JP. Brandel, B. Jarraya, L. Hopes, O. Rascol, JC. Corvol, D. Devos, AS. Rolland (Lille, France)

    Objective: As Parkinson’s disease progresses, patients require second-line treatments such as subthalamic stimulation, the benefits of which may be undermined by the appearance of non-dopaminergic…
  • 2025 International Congress

    Investigation of cortex – basal ganglia pathways with cortical stimulation and subthalamic evoked responses in patients with Parkinson’s disease

    J-C. Beyer, A. Cavallo, R M. Köhler, J. Vanhoecke, G-H. Schneider, A A. Kühn, W-J. Neumann (Berlin, Germany)

    Objective: To investigate the electrophysiological interplay between the human cortex and the subthalamic nucleus (STN) by comparing STN responses to direct cortical electrical stimulation and…
  • « Previous Page
  • 1
  • …
  • 372
  • 373
  • 374
  • 375
  • 376
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley